ArticleInternal medicine journal2026
Annual magnetic resonance cholangiopancreatography surveillance outcomes in individuals with primary sclerosing cholangitis.
Article in Internal medicine journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAnnual surveillance for cholangiocarcinoma using magnetic resonance cholangiopancreatography (MRCP) has been recommended in primary sclerosing cholangitis (PSC) to improve the associated dismal outcomes. However, data are limited.
aimsTo compare the outcomes of surveillance versus non-surveillance in patients with PSC.
methodsA retrospective cohort of patients with PSC at a liver transplant hospital with hepatologist-directed MRCP surveillance were identified. The surveillance group underwent a MRCP every 12 ± 3 months for at least 70% of the follow-up period. Patients were followed from their first MRCP to cholangiocarcinoma diagnosis, liver transplantation, death or the 30 April 2023.
resultsThe surveillance group with 108 patients (68%) and non-surveillance group with 50 patients (32%) were similar at baseline, with the median age at PSC diagnosis 38 years (range: 7-78 years), 91 males (59%) and the median duration of MRCP surveillance 86 months (range: 10-257 months). Cholangiocarcinoma was diagnosed in 14 patients (9%) (intrahepatic, n = 10; extrahepatic, n = 4). Surveillance MRCP detected one cholangiocarcinoma of the six patients diagnosed in the surveillance cohort, while 10 patients were diagnosed with cholangiocarcinoma following symptoms or raised liver enzymes. Overall, cumulative survival at 3 and 5 years was significantly improved in the surveillance group compared with the non-surveillance group in multivariate models, adjusting for age, cirrhosis and presence of cholangiocarcinoma (97% vs 77%, and 94% vs 69%, respectively; P < 0.001).
conclusionMRCP surveillance did not detect early cholangiocarcinoma or improve cholangiocarcinoma survival in this retrospective cohort of PSC patients; however, surveillance was associated with improved overall survival compared to no surveillance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.